Clinical trial
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
NCT00258739 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00258739 |
|---|---|
| Title | Docetaxel in Non Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II, Randomized Study With Docetaxel-gemcitabine Followed by Radiotherapy vs Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) Followed by Docetaxel-gemcitabine Versus Docetaxel-gemcitabine Followed by Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) in Stage III… |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug, Other |
| Interventions | Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine, Docetaxel + gemcitabine + carboplatin + radiotherapy |
| Enrollment | 140 |
| Start date | Oct 1, 2001 |
| Primary completion | Sep 1, 2007 |
| First posted | Nov 28, 2005 |
| Last update posted | Dec 7, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: